Desferoxamine

Desferoxamine

The primary drug used in iron chelation therapy. It aids in counteracting the life-threatening buildup of iron in the body associated with long-term blood transfusions.
Mentioned in: Thalassemia
References in periodicals archive ?
To control the iron levels in their bodies and protect their hearts, doctors at Philippine Children's Medical Center have placed the children on medication: Desferoxamine and Defereprone for both of them and Sumapen for Daisy.
Besides, the proposed scaffold has gradient changing construct, so a vertical gradient porosity along the thickness can be obtained which make it possible to realize spatially control release of desferoxamine (DFO).
The effect of desferoxamine and ferrostatin-1 on the cytotoxicity of artenimol of CCRF-CEM cells was determined by resazurin assays.
Therapeutic phlebotomies are more effective than either desferoxamine or EDTA.
Conditions predisposing to these infections include diabetes mellitus, hematologic malignancies, organ transplantation, steroid use, acquired immunodeficiency syndrome, treatment with desferoxamine, and iron overload.
Acquired factors include bone marrow expansion secondary to ineffective erythropiesis with cortical thinning, hypogonadotropic hypogonadism, hypothyroidism, hypoparathyroidism, diabetes mellitus, direct toxic effects of iron overload on osteoblast number and activity, deleterious effects of desferoxamine on the bone metabolism, the negative impact of chelation therapy on fibroblast proliferation and collagen synthesis, calcium and zinc deficiencies, low vitamin D levels due to aberrant vitamin D-parathyroid hormone axis and reduced physical activity (8-13).
The effects of desferoxamine and ascorbate on oxidative stress in the streptozotocin diabetic rat.
The only drug currently available for the clinical treatment of aluminum intoxication is a natural siderophore desferoxamine B (Hider et al.
6 Desferoxamine may reduce serum porphyrin levels in some patients while others may need renal transplantation to achieve complete resolution of the problem.
he team found high oxidative stress in mice with cerebral malaria and also found that treating them with and two antioxidant agents, desferoxamine and N-acetylcysteine prevented both inflammatory and vascular changes in the tissues of the brain, as well as the development of persistent cognitive damage.